ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Viral therapy"

  • 2020 American Transplant Congress

    Longer-Term Outcomes from the THINKER and EXPANDER Trials of Transplantation Using HCV-Viremic Kidneys

    V. S. Potluri1, F. Naqvi2, P. Reese1, M. Shah1, D. Brown2, S. Prenner1, A. Loupy3, A. Woodards1, P. Abt1, E. Blumberg1, J. Trofe-Clark1, D. Segev2, R. Bloom1, D. Sawinski1, C. Durand2, P. Porrett1, M. Levine1, D. Goldberg4, N. Desai2

    1University of Pennsylvania, Philadelphia, PA, 2Johns Hopkins, Baltimore, MD, 3Paris Transplant Group, Paris, France, 4University of Miami, Miami, FL

    *Purpose: The practice of transplanting HCV-viremic kidneys into HCV-negative recipients has become more common, but longer-term outcomes have not been reported. We present data on…
  • 2020 American Transplant Congress

    Access to Direct Acting Antiviral Therapy for Recipients of Solid Organs from Hepatitis C Viremic Donors

    C. Edmonds, A. Carver, J. DeClercq, L. Choi, M. Peter, R. Forbes, B. Concepcion, K. Schlendorf, R. Perri

    Vanderbilt University Medical Center, Nashville, TN

    *Purpose: Emerging data supports transplantation of organs from hepatitis C-positive (HCV) donors to expand the donor pool, but access to direct acting antivirals (DAAs) to…
  • 2020 American Transplant Congress

    Pharmacy Led Initiatives for Treatment of Transplant Recipients of Hepatitis C Viremic Donors in a High Volume Transplant Center

    H. Berry, J. Byrns, L. Crona, T. Capes, J. M. Steinbrink, E. K. Maziarz, C. R. Wolfe

    Duke University Medical Center, Durham, NC

    *Purpose: We describe a multidisciplinary workflow for initiation of hepatitis C virus (HCV) direct-acting antiviral (DAA) therapies post-transplant in the outpatient setting of a high…
  • 2020 American Transplant Congress

    Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors

    S. Bova1, A. Cameron1, C. Durand1, J. Katzianer2, M. LeGrand2, L. Boyer1, J. Glorioso3, L. P. Toman1

    1The Johns Hopkins Hospital, Baltimore, MD, 2Johns Hopkins Home Care Group, Baltimore, MD, 3Thomas Jefferson Univeristy Hospital, Philadelphia, PA

    *Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
  • 2020 American Transplant Congress

    Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation

    J. L. Saullo, A. Ferrari, E. M. Eichenberger, J. M. Steinbrink, A. W. Baker, M. Bacchus, E. K. Maziarz, S. Kakoullis, L. Zaffiri, H. Berry, J. M. Reynolds, C. R. Wolfe

    Duke University Medical Center, Durham, NC

    *Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…
  • 2020 American Transplant Congress

    Experience with a BKV-Specific, Neutralizing Monoclonal Antibody (MAU868) for Treatment of Severe BK Virus Nephropathy (BKVN) after Kidney Transplant (FDA EIND #139112)

    S. C. Jordan1, S. J. Kovacs2, J. R. Abend3, N. Ammerman1, M. Toyoda1, C. C. Nast1, E. Huang1, R. Najjar1, S. Sethi1, A. Peng1, K. Lim1, M. R. Hodges4, A. Vo1

    1Cedars Sinai Medical Ctr, Los Angeles, CA, 2Novartis Institutes for BioMedical Research, East Hanover, NJ, 3Novartis Institutes for BioMedical Research, Emeryville, CA, 4Amplyx Pharmaceuticals, San Diego, CA

    *Purpose: BK viral reactivation leading to nephropathy and allograft loss in kidney transplant recipients remains a significant challenge. No effective BKV-therapies are currently available. Management…
  • 2020 American Transplant Congress

    Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients

    K. Linder1, C. Kovacs2, K. Mullane3, C. Wolfe4, N. Clark5, C. Butkus Small6, R. La Hoz7, J. Smith8, C. Kotton9, A. Limaye10, M. Malinis11, M. Hakki12, A. Mishkin13, A. Gonzalez14, D. Kaul1

    1U Michigan, Ann Arbor, MI, 2Cleveland Clinic, Cleveland, OH, 3U Chicago, Chicago, IL, 4Duke, Durham, NC, 5Loyola, Chicago, IL, 6Cornell, NYC, NY, 7UTSW, Dallas, TX, 8U Wisconsin, Madison, WI, 9Mass General, Boston, MA, 10U Washington, Seattle, WA, 11Yale, New Haven, CT, 12OHSU, Portland, OR, 13Temple, Philadelphia, PA, 14West Coast ID, Safety Harbor, FL

    *Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…
  • 2020 American Transplant Congress

    The Effect of Undernutrition and Immunosuppression on Cytomegalovirus Specific T Cell Responses

    E. David1, M. Zhu2, W. Parker2, N. MacIver1, A. D. Kirk2, E. T. Chambers1

    1Pediatrics, Duke University, Durham, NC, 2Surgery, Duke University, Durham, NC

    *Purpose: Cytomegalovirus (CMV) infection remains a significant issue in transplantation, especially in those who are undernourished. While undernutrition is associated with impaired T cell immunity…
  • 2020 American Transplant Congress

    Clinical and Laboratory Characteristics of Early and Late-Onset Cytomegalovirus Infection Following Universal Prophylaxis in Kidney Transplant Recipients

    M. M. Tavakol, B. Lee, S. Ashimine, H. Crossman, M. Park, Z. Laszik, J. Roberts

    University of California, San Francisco, San Francisco, CA

    *Purpose: Cytomegalovirus (CMV) is the most important viral infection in organ recipients and can cause life-threatening infections, compromising long-term graft function. Most transplant centers use…
  • 2020 American Transplant Congress

    An OPO’s Experience in Increasing Transplantation with the Hope Project

    R. P. Wood, M. Ferguson, K. Myer, R. Cruz, P. Gillentine

    CMO, LifeGift, Houston, TX

    *Purpose: The purpose of this report is to describe one OPO’s experience in participating in the Hope Project. This research project is designed to evaluate…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 14
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences